FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988905992> ?p ?o ?g. }

• W1988905992 endingPage "14" @default.
• W1988905992 startingPage "1" @default.
• W1988905992 abstract "Mavacoxib is a novel nonsteroidal anti‐inflammatory drug ( NSAID ), with a preferential action on the cyclooxygenase ( COX )‐2 isoform of COX and a long duration of action. It is classified chemically as a member of the sulphonamide subgroup of coxibs. Mavacoxib is highly lipid but very poorly water soluble. In the dog, the pharmacokinetic ( PK ) profile comprises very slow body clearance, long elimination half‐life and a relatively large distribution volume. Biotransformation and renal excretion are very limited, and elimination occurs primarily by biliary secretion and excretion of unchanged drug in faeces. The PK profile of mavacoxib differs quantitatively between young healthy dogs (Beagles and mongrels) and clinical cases with osteoarthritis ( OA ). In OA dogs, mavacoxib exhibits a much longer terminal half‐life, associated principally with their greater median body weight compared with dogs used in preclinical studies. There is also some evidence of breed differences and a small effect of age on mavacoxib PK in the OA canine population. The pharmacodynamics ( PD ) of mavacoxib has been established: (i) in whole blood assays at the molecular level (inhibition of COX ‐1 and COX ‐2 isoforms); (ii) in preclinical models of inflammation and pain; and (iii) in clinical OA subjects treated with mavacoxib. The dosage schedule of mavacoxib for clinical use has been determined by owner and veterinary clinical assessments and is supported by integration of PK and PD preclinical data with clinical responses in canine disease models and in dogs with naturally occurring OA . The dosage regimen has been further confirmed by correlating levels of inhibition of COX isoforms in in vitro whole blood assays with plasma concentrations of mavacoxib achieved in OA dogs. In addition to the specific properties of mavacoxib, some general aspects of the PK and PD of other agents of the NSAID group, together with pathophysiological and clinical aspects of OA , are reviewed, as a basis for correlating with the safety and efficacy of mavacoxib in therapeutic use. Integration of PK and PD data suggests that the recommended dosage regimen of 2 mg/kg bw once for 14 days, followed by administration at monthly intervals, is optimal from both efficacy and safety perspectives and is further confirmed by clinical field studies." @default.
• W1988905992 created "2016-06-24" @default.
• W1988905992 creator A5007405150 @default.
• W1988905992 creator A5032052958 @default.
• W1988905992 creator A5032572523 @default.
• W1988905992 creator A5046171468 @default.
• W1988905992 creator A5056887296 @default.
• W1988905992 creator A5062854708 @default.
• W1988905992 date "2014-11-21" @default.
• W1988905992 modified "2023-10-10" @default.
• W1988905992 title "Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review" @default.
• W1988905992 cites W1485442945 @default.
• W1988905992 cites W1498305210 @default.
• W1988905992 cites W1566430257 @default.
• W1988905992 cites W1612226764 @default.
• W1988905992 cites W180197682 @default.
• W1988905992 cites W1962555352 @default.
• W1988905992 cites W1968766082 @default.
• W1988905992 cites W1974450761 @default.
• W1988905992 cites W1976278484 @default.
• W1988905992 cites W1979557331 @default.
• W1988905992 cites W1984271619 @default.
• W1988905992 cites W1995082781 @default.
• W1988905992 cites W1997208118 @default.
• W1988905992 cites W1997364548 @default.
• W1988905992 cites W2003599597 @default.
• W1988905992 cites W2004065216 @default.
• W1988905992 cites W2007342411 @default.
• W1988905992 cites W2008513973 @default.
• W1988905992 cites W2009228494 @default.
• W1988905992 cites W2016990891 @default.
• W1988905992 cites W2017785434 @default.
• W1988905992 cites W2027737914 @default.
• W1988905992 cites W2033498682 @default.
• W1988905992 cites W2038410983 @default.
• W1988905992 cites W2043755202 @default.
• W1988905992 cites W2047866592 @default.
• W1988905992 cites W2052001792 @default.
• W1988905992 cites W2057793539 @default.
• W1988905992 cites W2058336082 @default.
• W1988905992 cites W2063347675 @default.
• W1988905992 cites W2068551842 @default.
• W1988905992 cites W2069840586 @default.
• W1988905992 cites W2074107478 @default.
• W1988905992 cites W2075450464 @default.
• W1988905992 cites W2078588075 @default.
• W1988905992 cites W2083748640 @default.
• W1988905992 cites W2085067780 @default.
• W1988905992 cites W2089107052 @default.
• W1988905992 cites W2090285876 @default.
• W1988905992 cites W2095765195 @default.
• W1988905992 cites W2101492631 @default.
• W1988905992 cites W2107392877 @default.
• W1988905992 cites W2112768639 @default.
• W1988905992 cites W2113745276 @default.
• W1988905992 cites W2117558614 @default.
• W1988905992 cites W2121850944 @default.
• W1988905992 cites W2129827408 @default.
• W1988905992 cites W2132420892 @default.
• W1988905992 cites W2135291237 @default.
• W1988905992 cites W2140125412 @default.
• W1988905992 cites W2143572786 @default.
• W1988905992 cites W2146053956 @default.
• W1988905992 cites W2146605723 @default.
• W1988905992 cites W2151534353 @default.
• W1988905992 cites W2155674292 @default.
• W1988905992 cites W2157760679 @default.
• W1988905992 cites W2169667658 @default.
• W1988905992 cites W2191530456 @default.
• W1988905992 cites W4231421929 @default.
• W1988905992 doi "https://doi.org/10.1111/jvp.12185" @default.
• W1988905992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25413929" @default.
• W1988905992 hasPublicationYear "2014" @default.
• W1988905992 type Work @default.
• W1988905992 sameAs 1988905992 @default.
• W1988905992 citedByCount "18" @default.
• W1988905992 countsByYear W19889059922015 @default.
• W1988905992 countsByYear W19889059922016 @default.
• W1988905992 countsByYear W19889059922017 @default.
• W1988905992 countsByYear W19889059922018 @default.
• W1988905992 countsByYear W19889059922019 @default.
• W1988905992 countsByYear W19889059922020 @default.
• W1988905992 countsByYear W19889059922021 @default.
• W1988905992 countsByYear W19889059922022 @default.
• W1988905992 countsByYear W19889059922023 @default.
• W1988905992 crossrefType "journal-article" @default.
• W1988905992 hasAuthorship W1988905992A5007405150 @default.
• W1988905992 hasAuthorship W1988905992A5032052958 @default.
• W1988905992 hasAuthorship W1988905992A5032572523 @default.
• W1988905992 hasAuthorship W1988905992A5046171468 @default.
• W1988905992 hasAuthorship W1988905992A5056887296 @default.
• W1988905992 hasAuthorship W1988905992A5062854708 @default.
• W1988905992 hasConcept C111113717 @default.
• W1988905992 hasConcept C112705442 @default.
• W1988905992 hasConcept C126322002 @default.
• W1988905992 hasConcept C139254425 @default.
• W1988905992 hasConcept C2780035454 @default.
• W1988905992 hasConcept C2908647359 @default.

• next